121 related articles for article (PubMed ID: 38171333)
1. Metabolic switch regulates lineage plasticity and induces synthetic lethality in triple-negative breast cancer.
Zhang Y; Wu MJ; Lu WC; Li YC; Chang CJ; Yang JY
Cell Metab; 2024 Jan; 36(1):193-208.e8. PubMed ID: 38171333
[TBL] [Abstract][Full Text] [Related]
2. A Metabolic-Epigenetic Mechanism Directs Cell Fate and Therapeutic Sensitivity in Breast Cancer.
Bernard MJ; Goldstein AS
Cancer Res; 2024 May; 84(9):1382-1383. PubMed ID: 38330100
[TBL] [Abstract][Full Text] [Related]
3. LRPPRC promotes glycolysis by stabilising LDHA mRNA and its knockdown plus glutamine inhibitor induces synthetic lethality via m
Yu Y; Deng H; Wang W; Xiao S; Zheng R; Lv L; Wang H; Chen J; Zhang B
Clin Transl Med; 2024 Feb; 14(2):e1583. PubMed ID: 38372449
[TBL] [Abstract][Full Text] [Related]
4. METTL14/miR-29c-3p axis drives aerobic glycolysis to promote triple-negative breast cancer progression though TRIM9-mediated PKM2 ubiquitination.
Wu H; Jiao Y; Guo X; Wu Z; Lv Q
J Cell Mol Med; 2024 Feb; 28(3):e18112. PubMed ID: 38263865
[TBL] [Abstract][Full Text] [Related]
5. Metabolomic Rewiring Promotes Endocrine Therapy Resistance in Breast Cancer.
Ahn S; Park JH; Grimm SL; Piyarathna DWB; Samanta T; Putluri V; Mezquita D; Fuqua SAW; Putluri N; Coarfa C; Kaipparettu BA
Cancer Res; 2024 Jan; 84(2):291-304. PubMed ID: 37906431
[TBL] [Abstract][Full Text] [Related]
6. Silencing of Pyruvate Kinase M2
Huang S; Zhu W; Zhang F; Chen G; Kou X; Yang X; Ouyang G; Shen J
ACS Appl Mater Interfaces; 2021 Dec; 13(48):56972-56987. PubMed ID: 34797638
[TBL] [Abstract][Full Text] [Related]
7. Elucidating cancer metabolic plasticity by coupling gene regulation with metabolic pathways.
Jia D; Lu M; Jung KH; Park JH; Yu L; Onuchic JN; Kaipparettu BA; Levine H
Proc Natl Acad Sci U S A; 2019 Feb; 116(9):3909-3918. PubMed ID: 30733294
[TBL] [Abstract][Full Text] [Related]
8. Myoferlin regulates cellular lipid metabolism and promotes metastases in triple-negative breast cancer.
Blomme A; Costanza B; de Tullio P; Thiry M; Van Simaeys G; Boutry S; Doumont G; Di Valentin E; Hirano T; Yokobori T; Gofflot S; Peulen O; Bellahcène A; Sherer F; Le Goff C; Cavalier E; Mouithys-Mickalad A; Jouret F; Cusumano PG; Lifrange E; Muller RN; Goldman S; Delvenne P; De Pauw E; Nishiyama M; Castronovo V; Turtoi A
Oncogene; 2017 Apr; 36(15):2116-2130. PubMed ID: 27775075
[TBL] [Abstract][Full Text] [Related]
9. Combination Treatment Using Pyruvate Kinase M2 Inhibitors for the Sensitization of High Density Triple-negative Breast Cancer Cells.
Lee JS; Oh Y; Lee JS; Park JH; Shin JK; Han JH; Kim HS; Yoon S
In Vivo; 2022; 36(5):2105-2115. PubMed ID: 36099094
[TBL] [Abstract][Full Text] [Related]
10. CircWHSC1 regulates malignancy and glycolysis by the miR-212-5p/AKT3 pathway in triple-negative breast cancer.
Ding L; Xie Z
Exp Mol Pathol; 2021 Dec; 123():104704. PubMed ID: 34624276
[TBL] [Abstract][Full Text] [Related]
11. Targeting Pyruvate Kinase M2 Phosphorylation Reverses Aggressive Cancer Phenotypes.
Apostolidi M; Vathiotis IA; Muthusamy V; Gaule P; Gassaway BM; Rimm DL; Rinehart J
Cancer Res; 2021 Aug; 81(16):4346-4359. PubMed ID: 34185676
[TBL] [Abstract][Full Text] [Related]
12. TRAF6 promotes chemoresistance to paclitaxel of triple negative breast cancer via regulating PKM2-mediated glycolysis.
Xu H; Li L; Dong B; Lu J; Zhou K; Yin X; Sun H
Cancer Med; 2023 Oct; 12(19):19807-19820. PubMed ID: 37746908
[TBL] [Abstract][Full Text] [Related]
13. Aurora-A/ERK1/2/mTOR axis promotes tumor progression in triple-negative breast cancer and dual-targeting Aurora-A/mTOR shows synthetic lethality.
Zhang W; Xia D; Li Z; Zhou T; Chen T; Wu Z; Zhou W; Li Z; Li L; Xu J
Cell Death Dis; 2019 Aug; 10(8):606. PubMed ID: 31406104
[TBL] [Abstract][Full Text] [Related]
14. Dual target PARP1/EZH2 inhibitors inducing excessive autophagy and producing synthetic lethality for triple-negative breast cancer therapy.
Li X; Wang C; Li S; Yin F; Luo H; Zhang Y; Luo Z; Chen Y; Wan S; Kong L; Wang X
Eur J Med Chem; 2024 Feb; 265():116054. PubMed ID: 38134746
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer.
Camarda R; Zhou AY; Kohnz RA; Balakrishnan S; Mahieu C; Anderton B; Eyob H; Kajimura S; Tward A; Krings G; Nomura DK; Goga A
Nat Med; 2016 Apr; 22(4):427-32. PubMed ID: 26950360
[TBL] [Abstract][Full Text] [Related]
16. BETi enhance ATGL expression and its lipase activity to exert their antitumoral effects in triple-negative breast cancer (TNBC) cells.
Rossi T; Zamponi R; Chirico M; Pisanu ME; Iorio E; Torricelli F; Gugnoni M; Ciarrocchi A; Pistoni M
J Exp Clin Cancer Res; 2023 Jan; 42(1):7. PubMed ID: 36604676
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of CDCA7 predicts poor prognosis and induces EZH2-mediated progression of triple-negative breast cancer.
Ye L; Li F; Song Y; Yu D; Xiong Z; Li Y; Shi T; Yuan Z; Lin C; Wu X; Ren L; Li X; Song L
Int J Cancer; 2018 Nov; 143(10):2602-2613. PubMed ID: 30151890
[TBL] [Abstract][Full Text] [Related]
18. Mitochondrial dysfunction in some triple-negative breast cancer cell lines: role of mTOR pathway and therapeutic potential.
Pelicano H; Zhang W; Liu J; Hammoudi N; Dai J; Xu RH; Pusztai L; Huang P
Breast Cancer Res; 2014 Sep; 16(5):434. PubMed ID: 25209360
[TBL] [Abstract][Full Text] [Related]
19. Discovery of a novel dual-target inhibitor of CDK12 and PARP1 that induces synthetic lethality for treatment of triple-negative breast cancer.
Zhang L; Zhen Y; Feng L; Li Z; Lu Y; Wang G; Ouyang L
Eur J Med Chem; 2023 Nov; 259():115648. PubMed ID: 37478560
[TBL] [Abstract][Full Text] [Related]
20. Novel Aza-podophyllotoxin derivative induces oxidative phosphorylation and cell death via AMPK activation in triple-negative breast cancer.
Tailor D; Going CC; Resendez A; Kumar V; Nambiar DK; Li Y; Dheeraj A; LaGory EL; Ghoochani A; Birk AM; Stoyanova T; Ye J; Giaccia AJ; Le QT; Singh RP; Sledge GW; Pitteri SJ; Malhotra SV
Br J Cancer; 2021 Feb; 124(3):604-615. PubMed ID: 33139797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
